SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Narowski, Tara M.
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
  • Raphel, Kristin
    • Other Affiliation: George Washington University School of Medicine
  • Adams, Lily E.
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
  • Huang, Jenny
    • Other Affiliation: George Washington University School of Medicine
  • Vielot, Nadja A.
    • Affiliation: School of Medicine, Department of Family Medicine
  • Jadi, Ramesh
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
  • de Silva, Aravinda M.
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
  • Baric, Ralph S.
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
  • Lafleur, John E.
    • Other Affiliation: George Washington University School of Medicine
  • Premkumar, Lakshmanane
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
Abstract
  • Understanding vaccine-mediated protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to overcoming the global coronavirus disease 2019 (COVID-19) pandemic. We investigate mRNA-vaccine-induced antibody responses against the reference strain, seven variants, and seasonal coronaviruses in 168 healthy individuals at three time points: before vaccination, after the first dose, and after the second dose. Following complete vaccination, both naive and previously infected individuals developed comparably robust SARS-CoV-2 spike antibodies and variable levels of cross-reactive antibodies to seasonal coronaviruses. However, the strength and frequency of SARS-CoV-2 neutralizing antibodies in naive individuals were lower than in previously infected individuals. After the first vaccine dose, one-third of previously infected individuals lacked neutralizing antibodies; this was improved to one-fifth after the second dose. In all individuals, neutralizing antibody responses against the Alpha and Delta variants were weaker than against the reference strain. Our findings support future tailored vaccination strategies against emerging SARS-CoV-2 variants as mRNA-vaccine-induced neutralizing antibodies are highly variable among individuals.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution-NonCommercial-NoDerivs 3.0 United States
Journal title
  • Cell Reports
Journal volume
  • 38
Language
  • English
Version
  • Publisher
ISSN
  • 2211-1247

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 1-s2.0-S2211124722000523-main.pdf 2022-02-01 Public Download